Emily Bodnar
Stock Analyst at HC Wainwright & Co.
(1.11)
# 3,811
Out of 5,182 analysts
326
Total ratings
26.71%
Success rate
-14.03%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Emily Bodnar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INKT MiNK Therapeutics | Reiterates: Buy | $35 | $11.04 | +217.03% | 15 | Apr 1, 2026 | |
| ANAB AnaptysBio | Reiterates: Buy | $66 | $70.10 | -5.85% | 15 | Mar 30, 2026 | |
| ATOS Atossa Therapeutics | Maintains: Buy | $7 → $25 | $4.94 | +406.07% | 15 | Mar 26, 2026 | |
| PPBT Purple Biotech | Maintains: Buy | $34 → $30 | $4.13 | +626.39% | 15 | Mar 13, 2026 | |
| SABS SAB Biotherapeutics | Maintains: Buy | $9 → $7 | $3.75 | +86.67% | 3 | Mar 10, 2026 | |
| OLMA Olema Pharmaceuticals | Maintains: Buy | $36 → $38 | $16.10 | +136.02% | 24 | Mar 9, 2026 | |
| SANA Sana Biotechnology | Maintains: Buy | $9 → $7 | $3.09 | +126.54% | 13 | Mar 4, 2026 | |
| RCUS Arcus Biosciences | Reiterates: Buy | $32 | $22.34 | +43.24% | 8 | Mar 2, 2026 | |
| NVCR NovoCure | Maintains: Buy | $47 → $49 | $10.58 | +363.14% | 22 | Feb 26, 2026 | |
| ACLX Arcellx | Downgrades: Neutral | $115 | $114.83 | +0.15% | 15 | Feb 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $1.49 | +504.03% | 1 | Feb 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $62 → $65 | $32.92 | +97.45% | 5 | Feb 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $47 | $36.56 | +28.56% | 3 | Dec 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $19 | $1.56 | +1,117.95% | 13 | Nov 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $15 | $6.81 | +120.26% | 2 | Nov 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $5 | $2.49 | +100.80% | 13 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $0.87 | +1,274.73% | 1 | Oct 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $60 | $33.73 | +77.88% | 1 | Oct 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $3.96 | +480.81% | 20 | Sep 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $40 | $4.28 | +834.58% | 15 | Aug 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $8 | $0.40 | +1,915.11% | 25 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $20 | $0.80 | +2,392.83% | 10 | Jul 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $36 | $11.64 | +209.28% | 9 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $560 → $280 | $8.21 | +3,310.48% | 17 | Apr 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $2.82 | +183.69% | 6 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $2.54 | +1,081.10% | 7 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $2.17 | +729.49% | 15 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $183 | $2.92 | +6,153.77% | 12 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $1.67 | - | 5 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $1.97 | - | 1 | Apr 25, 2024 |
MiNK Therapeutics
Apr 1, 2026
Reiterates: Buy
Price Target: $35
Current: $11.04
Upside: +217.03%
AnaptysBio
Mar 30, 2026
Reiterates: Buy
Price Target: $66
Current: $70.10
Upside: -5.85%
Atossa Therapeutics
Mar 26, 2026
Maintains: Buy
Price Target: $7 → $25
Current: $4.94
Upside: +406.07%
Purple Biotech
Mar 13, 2026
Maintains: Buy
Price Target: $34 → $30
Current: $4.13
Upside: +626.39%
SAB Biotherapeutics
Mar 10, 2026
Maintains: Buy
Price Target: $9 → $7
Current: $3.75
Upside: +86.67%
Olema Pharmaceuticals
Mar 9, 2026
Maintains: Buy
Price Target: $36 → $38
Current: $16.10
Upside: +136.02%
Sana Biotechnology
Mar 4, 2026
Maintains: Buy
Price Target: $9 → $7
Current: $3.09
Upside: +126.54%
Arcus Biosciences
Mar 2, 2026
Reiterates: Buy
Price Target: $32
Current: $22.34
Upside: +43.24%
NovoCure
Feb 26, 2026
Maintains: Buy
Price Target: $47 → $49
Current: $10.58
Upside: +363.14%
Arcellx
Feb 23, 2026
Downgrades: Neutral
Price Target: $115
Current: $114.83
Upside: +0.15%
Feb 17, 2026
Initiates: Buy
Price Target: $9
Current: $1.49
Upside: +504.03%
Feb 12, 2026
Maintains: Buy
Price Target: $62 → $65
Current: $32.92
Upside: +97.45%
Dec 19, 2025
Maintains: Buy
Price Target: $36 → $47
Current: $36.56
Upside: +28.56%
Nov 25, 2025
Reiterates: Buy
Price Target: $19
Current: $1.56
Upside: +1,117.95%
Nov 12, 2025
Maintains: Buy
Price Target: $12 → $15
Current: $6.81
Upside: +120.26%
Nov 6, 2025
Maintains: Buy
Price Target: $4 → $5
Current: $2.49
Upside: +100.80%
Oct 14, 2025
Initiates: Buy
Price Target: $12
Current: $0.87
Upside: +1,274.73%
Oct 6, 2025
Assumes: Buy
Price Target: $60
Current: $33.73
Upside: +77.88%
Sep 10, 2025
Reiterates: Buy
Price Target: $23
Current: $3.96
Upside: +480.81%
Aug 27, 2025
Maintains: Buy
Price Target: $32 → $40
Current: $4.28
Upside: +834.58%
Aug 11, 2025
Maintains: Buy
Price Target: $12 → $8
Current: $0.40
Upside: +1,915.11%
Jul 7, 2025
Maintains: Buy
Price Target: $40 → $20
Current: $0.80
Upside: +2,392.83%
Jul 1, 2025
Reiterates: Buy
Price Target: $36
Current: $11.64
Upside: +209.28%
Apr 16, 2025
Maintains: Buy
Price Target: $560 → $280
Current: $8.21
Upside: +3,310.48%
Apr 1, 2025
Reiterates: Buy
Price Target: $8
Current: $2.82
Upside: +183.69%
Mar 31, 2025
Reiterates: Buy
Price Target: $30
Current: $2.54
Upside: +1,081.10%
Mar 27, 2025
Reiterates: Buy
Price Target: $18
Current: $2.17
Upside: +729.49%
Mar 26, 2025
Reiterates: Buy
Price Target: $183
Current: $2.92
Upside: +6,153.77%
Mar 12, 2025
Reiterates: Neutral
Price Target: n/a
Current: $1.67
Upside: -
Apr 25, 2024
Reiterates: Neutral
Price Target: n/a
Current: $1.97
Upside: -